Inhaled fixed-dose combination powders for the treatment of respiratory infections

References

• Troeger C, Blacker B, Khalil IA, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis. 2018;18(11):1191–1210.
   PubMed Web of Science ®Google Scholar
• Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1151–1210.
   PubMed Web of Science ®Google Scholar
• Boisson M, Jacobs M, Grégoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58(12):7331–7339.
   PubMed Web of Science ®Google Scholar
• Braunstein M, Hickey AJ, Ekins S. Why wait? the case for treating tuberculosis with inhaled drugs. Pharm Res. 2019;36(12):166.
   PubMed Web of Science ®Google Scholar
• Tolman JA, Williams RO 3rd. Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties. Drug Dev Ind Pharm. 2010;36(1):1–30.
   PubMed Web of Science ®Google Scholar
• Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013;31(3):177–184.
   PubMed Web of Science ®Google Scholar
• BTS. SIGN 158: British guideline on management of asthma [Online]. UK: The British Thoracic Society. 2019. [Available from: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/
   Google Scholar
• GOLD. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019. Contract No.: 2019 Nov 15.
   Google Scholar
• Brunaugh AD, Smyth HDC. Formulation techniques for high dose dry powders. Int J Pharm. 2018;547(1–2):489–498.
   PubMedGoogle Scholar
• Weers J. Inhaled antimicrobial therapy - barriers to effective treatment. Adv Drug Deliv Rev. 2015;85:24–43.
   PubMed Web of Science ®Google Scholar
• Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm pseudomonas aeruginosa. J Infect Dis. 2010;202(10):1585–1592.
   PubMed Web of Science ®Google Scholar
• Trapnell BC, McColley SA, Ker DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med. 2012;185(2):171–178.
   PubMed Web of Science ®Google Scholar
• Traugott KA, Echevarria K, Maxwell P, et al. Monotherapy or combination therapy? the pseudomonas aeruginosa conundrum. Pharmacother J Human Pharmacol Drug Ther. 2011;31(6):598–608.
   Google Scholar
• Mouton JW. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection. 1999;27(S2):S24–S8.
   PubMedGoogle Scholar
• Lenhard JR, Nation RL, Tsuji BT. Synergistic combinations of polymyxins. Int J Antimicrob Agents. 2016;48(6):607–613.
   PubMed Web of Science ®Google Scholar
• Zheng W, Sun W, Simeonov A. Drug repurposing screens and synergistic drug-combinations for infectious diseases. Br J Pharmacol. 2018;175(2):181–191.
   PubMed Web of Science ®Google Scholar
• Muralidharan N, Sakthivel R, Velmurugan D, et al. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J Biomol Struct Dyn. 2020;1–6. 10.1080/07391102.2020.1752802.
   PubMed Web of Science ®Google Scholar
• Pechere JC, Hughes D, Kardas P, et al. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents. 2007;29(3):245–253.
   PubMed Web of Science ®Google Scholar
• van Galen KA, Nellen JF, Nieuwkerk PT. The effect on treatment adherence of administering drugs as fixed-dose combinations versus as separate pills: systematic review and meta-analysis. AIDS Res Treat. 2014;2014:967073.
   PubMedGoogle Scholar
• Kauf TL, Davis KL, Earnshaw SR, et al. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012;6:155–164.
   PubMed Web of Science ®Google Scholar
• Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline: executive summary. Clin Infect Dis. 2020. 4. 10.1093/cid/ciaa1125.
   Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2019. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, Switzerland: World Health Organization; 2019.
   Google Scholar
• Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother. 2009;10(3):381–401.
   PubMed Web of Science ®Google Scholar
• Albanna AS, Smith BM, Cowan D, et al. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013;42(3):721–732.
   PubMed Web of Science ®Google Scholar
• Mogayzel PJ Jr., Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–689.
   PubMed Web of Science ®Google Scholar
• O’Donohoe R, Fullen BM. Adherence of subjects with cystic fibrosis to their home program: a systematic review. Respir Care. 2014;59(11):1731–1746.
   PubMed Web of Science ®Google Scholar
• Latchford G, Duff A, Quinn J, et al. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns. 2009;75(1):141–144.
   PubMed Web of Science ®Google Scholar
• Schneider EK, Azad MA, Han ML, et al. An “unlikely” pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI. ACS Infect Dis. 2016;2(7):478–488.
   PubMed Web of Science ®Google Scholar
• Akdag Cayli Y, Sahin S, Buttini F, et al. Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients. Drug Dev Ind Pharm. 2017;43(8):1378–1389.
   PubMed Web of Science ®Google Scholar
• Yang Y, Tsifansky MD, Wu CJ, et al. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res. 2010;27(1):151–160.
   PubMed Web of Science ®Google Scholar
• Ragaller M, Richter T. Acute lung injury and acute respiratory distress syndrome. J Emerg Trauma Shock. 2010;3(1):43–51.
   PubMedGoogle Scholar
• Tisoncik JR, Korth MJ, Simmons CP, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012;76(1):16–32.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
   PubMed Web of Science ®Google Scholar
• Antunes G, Evans SA, Lordan JL, et al. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002;20(4):990.
   PubMed Web of Science ®Google Scholar
• Padrones S, Garcia-Vidal C, Fernandez-Serrano S, et al. Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis. 2010;29(10):1243–1251.
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect. 2011;63(3):187–199.
   PubMed Web of Science ®Google Scholar
• Kudo K, Takasaki J, Manabe T, et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS One. 2012;7(2):e32280.
   PubMed Web of Science ®Google Scholar
• Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269–270.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. New England Journal of Medicine. 2020.
   Google Scholar
• Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212(9):416–420.
   PubMed Web of Science ®Google Scholar
• King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?. Drugs. 2007;67(7):965–974.
   PubMed Web of Science ®Google Scholar
• Lee SH, Teo J, Heng D, et al. Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy. J Pharm Sci. 2014;103(4):1115–1125.
   PubMed Web of Science ®Google Scholar
• Steel HC, Theron AJ, Cockeran R, et al. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm. 2012;2012:584262.
   PubMed Web of Science ®Google Scholar
• Fan LC, Xu JF. Advantages and drawbacks of long-term macrolide use in the treatment of non-cystic fibrosis bronchiectasis. J Thorac Dis. 2014;6(7):867–871.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Loh ZH, Yu J, et al. How much surface coating of hydrophobic azithromycin is sufficient to prevent moisture-induced decrease in aerosolisation of hygroscopic amorphous colistin powder?. Aaps J. 2016;18(5):1213–1224.
   PubMed Web of Science ®Google Scholar
• Rampacci E, Marenzoni ML, Chiaradia E, et al. In vitro performances of novel co-spray-dried azithromycin/rifampicin microparticles for rhodococcus equi disease treatment. Sci Rep. 2018;8(1):12149.
   PubMedGoogle Scholar
• Mangal S, Xu R, Park H, et al. Understanding the impacts of surface compositions on the in-vitro dissolution and aerosolization of co-spray-dried composite powder formulations for Inhalation. Pharm Res. 2018;36(1):6.
   PubMed Web of Science ®Google Scholar
• Yazdi AK, Smyth HDC. Carrier-free high-dose dry powder inhaler formulation of ibuprofen: physicochemical characterization and in vitro aerodynamic performance. Int J Pharm. 2016;511(1):403–414.
   PubMedGoogle Scholar
• Chan EWL, Yee ZY, Raja I, et al. Synergistic effect of non-steroidal anti-inflammatory drugs (NSAIDs) on antibacterial activity of cefuroxime and chloramphenicol against methicillin-resistant staphylococcus aureus. J Glob Antimicrob Resist. 2017;10:70–74.
   PubMed Web of Science ®Google Scholar
• Oliveira IM, Borges A, Borges F, et al. Repurposing ibuprofen to control Staphylococcus aureus biofilms. Eur J Med Chem. 2019;166:197–205.
   PubMed Web of Science ®Google Scholar
• Bradbury P, Traini D, Ammit AJ, et al. Repurposing of statins via inhalation to treat lung inflammatory conditions. Adv Drug Deliv Rev. 2018;133:93–106.
   PubMed Web of Science ®Google Scholar
• Masadeh M, Mhaidat N, Alzoubi K, et al. Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob. 2012;11(1):13.
   PubMed Web of Science ®Google Scholar
• Momin MAM, Tucker IG, Doyle CS, et al. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug. Int J Pharm. 2018;543(1–2):318–327.
   PubMedGoogle Scholar
• Zhou QT, Morton DA, Yu HH, et al. Colistin powders with high aerosolisation efficiency for respiratory infection: preparation and in vitro evaluation. J Pharm Sci. 2013;102(10):3736–3747.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Sun S-P, Chan JGY, et al. Novel inhaled combination powder containing amorphous colistin and crystalline rifapentine with enhanced antimicrobial activities against planktonic cells and biofilm of pseudomonas aeruginosa for respiratory infections. Mol Pharm. 2015;12(8):2594–2603.
   PubMedGoogle Scholar
• Zhou Q, Gengenbach T, Denman JA, et al. Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection. Am Assoc Pharm Sci J. 2014;16(1):37–47.
   Google Scholar
• Tiddens HA, Bos AC, Mouton JW, et al. Inhaled antibiotics: dry or wet?. Eur Respir J. 2014;44(5):1308–1318.
   PubMed Web of Science ®Google Scholar
• Kamin W, Erdnuss F, Kramer I. Inhalation solutions–which ones may be mixed? physico-chemical compatibility of drug solutions in nebulizers–update 2013. J Cyst Fibros. 2014;13(3):243–250.
   PubMed Web of Science ®Google Scholar
• Brunaugh AD, Jan SU, Ferrati S, et al. Excipient-free pulmonary delivery and macrophage targeting of clofazimine via air jet micronization. Mol Pharm. 2017;14(11):4019–4031.
   PubMed Web of Science ®Google Scholar
• de Boer AH, Hagedoorn P. The role of disposable inhalers in pulmonary drug delivery. Expert Opin Drug Deliv. 2015;12(1):143–157.
   PubMed Web of Science ®Google Scholar
• Lavorini F, Pistolesi M, Usmani OS. Recent advances in capsule-based dry powder inhaler technology. Multidiscip Respir Med. 2017;12(1):11.
   PubMedGoogle Scholar
• Ari A, Fink JB. Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin Drug Deliv. 2020;17(2):133–144.
   PubMed Web of Science ®Google Scholar
• Chandel A, Goyal AK, Ghosh G, et al. Recent advances in aerosolised drug delivery. Biomed Pharmacother. 2019;112:108601.
   PubMed Web of Science ®Google Scholar
• Chan JG, Chan HK, Prestidge CA, et al. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. Eur J Pharm Biopharm. 2013;83(2):285–292.
   PubMed Web of Science ®Google Scholar
• Chan JG, Tyne AS, Pang A, et al. A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. Pharm Res. 2014;31(5):1239–1253.
   PubMed Web of Science ®Google Scholar
• Chadha R, Bhandari S. Drug-excipient compatibility screening–role of thermoanalytical and spectroscopic techniques. J Pharm Biomed Anal. 2014;87:82–97.
   PubMed Web of Science ®Google Scholar
• Drlica K, Zhao X, Kreiswirth B. Minimising moxifloxacin resistance with tuberculosis. Lancet Infect Dis. 2008;8(5):273–275.
   PubMed Web of Science ®Google Scholar
• Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet. 1999;353(9167):1843–1847.
   PubMed Web of Science ®Google Scholar
• GROSSET J, LOUNIS N, TRUFFOT-PERNOT C, et al. Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice. Am J Respir Crit Care Med. 1998;157(5):1436–1440.
   PubMed Web of Science ®Google Scholar
• Zhou QT, Sun SP, Chan JG, et al. Novel inhaled combination powder containing amorphous colistin and crystalline rifapentine with enhanced antimicrobial activities against planktonic cells and biofilm of pseudomonas aeruginosa for respiratory infections. Mol Pharm. 2015;12(8):2594–2603.
   PubMedGoogle Scholar
• Chan JG, Tyne AS, Pang A, Duke C, Britton WJ, Chan HK, et al. An inhalable rifapentine dry powder targeting latent tuberculosis infection. Journal of aerosol medicine and pulmonary drug delivery. ,2014;27(4):A12-A3.
   Google Scholar
• Beck-Broichsitter M, Merkel OM, Kissel T. Controlled pulmonary drug and gene delivery using polymeric nano-carriers. J Control Release. 2012;161(2):214–224.
   PubMed Web of Science ®Google Scholar
• Daher EF, Marques CN, Lima RS, et al. Acute kidney injury in an infectious disease intensive care unit-an assessment of prognostic factors. Swiss Med Wkly. 2008;138(9–10).
   PubMed Web of Science ®Google Scholar
• Akram AR, Singanayagam A, Choudhury G, et al. Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia. Chest. 2010;138(4):825–832.
   PubMed Web of Science ®Google Scholar
• Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67–74.
   PubMed Web of Science ®Google Scholar
• Yeung S, Traini D, Tweedie A, et al. Limitations of high dose carrier based formulations. Int J Pharm. 2018;544(1):141–152.
   PubMedGoogle Scholar
• Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1–2):1–19.
   PubMed Web of Science ®Google Scholar
• FDA. Guidance for Industry: nonclinical Studies for theSafety Evaluation ofPharmaceutical Excipients. United States of America: U.S. Department of Health and Human Services; 2005.
   Google Scholar
• Weers J, Clark A. The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers. Pharm Res. 2017;34(3):507–528.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. 15. 10.1093/cid/ciaa248.
   Web of Science ®Google Scholar
• Jetmalani K, Young PM, Smith T, et al. Micronized drug powders in binary mixtures and the effect of physical properties on aerosolization from combination drug dry powder inhalers. Drug Dev Ind Pharm. 2012;38(12):1504–1511.
   PubMed Web of Science ®Google Scholar
• Begat P, Price R, Harris H, et al. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA Powder Part J. 2005;23:109–121.
   Google Scholar
• Begat P, Morton DA, Shur J, et al. The role of force control agents in high-dose dry powder inhaler formulations. J Pharm Sci. 2009;98(8):2770–2783.
   PubMed Web of Science ®Google Scholar
• Lau M, Young PM, Traini D. A review of co-milling techniques for the production of high dose dry powder inhaler formulation. Drug Dev Ind Pharm. 2017;43(8):1229–1238.
   PubMed Web of Science ®Google Scholar
• Lobmann K, Strachan C, Grohganz H, et al. Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions. Eur J Pharm Biopharm. 2012;81(1):159–169.
   PubMed Web of Science ®Google Scholar
• Wairkar S, Gaud R. Co-Amorphous combination of Nateglini de-Metformin Hydrochloride for dissolution enhancement. AAPS PharmSciTech. 2016;17(3):673–681.
   PubMed Web of Science ®Google Scholar
• Chieng N, Aaltonen J, Saville D, et al. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation. Eur J Pharm Biopharm. 2009;71(1):47–54.
   PubMed Web of Science ®Google Scholar
• Alleso M, Chieng N, Rehder S, et al. Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen-cimetidine mixtures prepared by mechanical activation. J Control Release. 2009;136(1):45–53.
   PubMed Web of Science ®Google Scholar
• Lobmann K, Laitinen R, Grohganz H, et al. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen. Mol Pharm. 2011;8(5):1919–1928.
   PubMed Web of Science ®Google Scholar
• Morton D, Staniforth J, inventors; Vectura Limited, assignee. Dry powder composition comprising co-jet milled particles for pulmonary inhalation. United States patent US. 8,182,838 B2 2012.
   Google Scholar
• Chen L, Okuda T, Lu XY, et al. Amorphous powders for inhalation drug delivery. Adv Drug Deliv Rev. 2016;100:102–115.
   PubMed Web of Science ®Google Scholar
• Adi H, Young PM, Chan HK, et al. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci. 2008;97(8):3356–3366.
   PubMed Web of Science ®Google Scholar
• Eedara BB, Rangnekar B, Sinha S, et al. Development and characterization of high payload combination dry powders of anti-tubercular drugs for treating pulmonary tuberculosis. Eur J Pharm Sci. 2018;118:216–226.
   PubMed Web of Science ®Google Scholar
• Lee SH, Teo J, Heng D, et al. Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation. Eur J Pharm Biopharm. 2013;83(2):275–284.
   PubMed Web of Science ®Google Scholar
• Muttil P, Kaur J, Kumar K, et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur J Pharm Sci. 2007;32(2):140–150.
   PubMed Web of Science ®Google Scholar
• Tsifansky MD, Yeo Y, Evgenov OV, et al. Microparticles for inhalational delivery of antipseudomonal antibiotics. Aaps J. 2008;10(2):254–260.
   PubMed Web of Science ®Google Scholar
• Lee SH, Teo J, Heng D, et al. Tailored antibiotic combination powders for inhaled rotational antibiotic therapy. J Pharm Sci. 2016;105(4). 10.1016/j.xphs.2016.02.007.
   Web of Science ®Google Scholar
• Rangnekar B, Momin MAM, Eedara BB, et al. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. Int J Pharm. 2019;570:118689.
   PubMed Web of Science ®Google Scholar
• Learoyd TP, Burrows JL, French E, et al. Sustained delivery by leucine-modified chitosan spray-dried respirable powders. Int J Pharm. 2009;372(1–2):97–104.
   PubMedGoogle Scholar
• Lee SH, Teo J, Heng D, et al. A novel inhaled multi-pronged attack against respiratory bacteria. Eur J Pharm Sci. 2015;70:37–44.
   PubMed Web of Science ®Google Scholar
• Pilcer G, De Bueger V, Traina K, et al. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. Int J Pharm. 2013;451(1–2):112–120.
   PubMedGoogle Scholar
• Pilcer G, Rosiere R, Traina K, et al. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. J Pharm Sci. 2013;102(6):1836–1846.
   PubMed Web of Science ®Google Scholar
• Johnson NR, Wang Y. Coacervate delivery systems for proteins and small molecule drugs. Expert Opin Drug Deliv. 2014;11(12):1829–1832.
   PubMed Web of Science ®Google Scholar
• Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray drying. J Aerosol Sci. 2007;38(7):728–746.
   Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999–1022.
   PubMed Web of Science ®Google Scholar
• Boraey MA, Vehring R. Diffusion controlled formation of microparticles. J Aerosol Sci. 2014;67:131–143.
   Web of Science ®Google Scholar
• Food and Drug Administration. Regulatory Classification of Pharmaceutical Co-Crystals Guidance for Industry. Silver Spring, MD2018. p. 1–4.
   Google Scholar
• Sekhon BS. Drug-drug co-crystals. Daru. 2012;20(1):45.
   PubMedGoogle Scholar
• Karimi-Jafari M, Padrela L, Walker GM, et al. Creating cocrystals: a review of pharmaceutical cocrystal preparation routes and applications. Cryst Growth Des. 2018;18(10):6370–6387.
   Web of Science ®Google Scholar
• Jin F, Hindle M, Byron P. Co-deposition of Albuterol Sulfate - Ipratropium Bromide Co-Crystal Aerosols. Respir Drug Delivery Eur. 2007;1:373–376.
   Google Scholar
• Alhalaweh A, Kaialy W, Buckton G, et al. Theophylline cocrystals prepared by spray drying: physicochemical properties and aerosolization performance. AAPS PharmSciTech. 2013;14(1):265–276.
   PubMed Web of Science ®Google Scholar
• Lu J, Rohani S. Synthesis and preliminary characterization of sulfamethazine-theophylline co-crystal. J Pharm Sci. 2010;99(9):4042–4047.
   PubMed Web of Science ®Google Scholar
• Ray E, Vaghasiya K, Sharma A, et al. Autophagy-inducing inhalable co-crystal formulation of Niclosamide-Nicotinamide for lung cancer therapy. AAPS PharmSciTech. 2020;21(7):260.
   PubMed Web of Science ®Google Scholar
• Iqbal M, Zafar N, Fessi H, et al. Double emulsion solvent evaporation techniques used for drug encapsulation. Int J Pharm. 2015;496(2):173–190.
   PubMed Web of Science ®Google Scholar
• Bunker A, Magarkar A, Viitala T. Rational design of liposomal drug delivery systems, a review: combined experimental and computational studies of lipid membranes, liposomes and their PEGylation. Biochim Biophys Acta. 2016;1858(10):2334–2352.
   PubMed Web of Science ®Google Scholar
• Rose SJ, Neville ME, Gupta R, et al. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS One. 2014;9(9):e108703.
   PubMed Web of Science ®Google Scholar
• Zhang J, Leifer F, Rose S, et al. Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol. 2018;9:915.
   PubMed Web of Science ®Google Scholar
• Yu S, Wang S, Zou P, et al. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections. Int J Pharm. 2020;575:118915.
   PubMedGoogle Scholar
• Overhoff K, Johnston K, Tam J, et al. Use of thin film freezing to enable drug delivery: a review. J Drug Delivery Sci Technol. 2009;19(2):89–98.
   Web of Science ®Google Scholar
• Liu S, Watts AB, Du J, et al. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery. Eur J Pharm Biopharm. 2015;96:132–142.
   PubMed Web of Science ®Google Scholar
• Carvalho S. Improved Inhalation Therapies of Brittle Powders. Austin, Texas: University of Texas at Austin; 2013.
   Google Scholar